Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.

Authors : Pritchard KI, Burris HA, Ito Y, Rugo HS, Dakhil S, Hortobagyi GN, Campone M, Csöszi T, Baselga J, Puttawibul P, Piccart-Gebhart M, Heng D, Noguchi S, Srimuninnimit V, Bourgeois H, Gonzalez Martin A, Osborne K, Panneerselvam A, Taran T, Sahmoud T, Gnant M
Year : 2013
Journal : Clin Breast Cancer
Volume : 13(6)
Pages : 421-432.e8

Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial.

Authors : Partridge AH, Gelber S, Piccart-Gebhart M, Focant F, Scullion M, Holmes E, Winer EP, Gelber Rd
Year : 2013
Journal : J. Clin. Oncol.
Volume : 31(21)
Pages : 2692-8

Why your preferred targeted drugs may become unaffordable.

Authors : Piccart-Gebhart M
Year : 2013
Journal : Cancer Res
Volume : 73(19)
Pages : 5849-51

Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial.

Authors : de Azambuja E, Zardavas D, Lemort M, Rossari J, Moulin C, Buttice A, Dhondt V, Lebrun F, Lalami Y, Cardoso F, Sotiriou C, Gil T, Devriendt D, Paesmans M, Piccart-Gebhart M, Awada A
Year : 2013
Journal : Ann Oncol
Volume : 24(12)
Pages : 2985-9

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.

Authors : Goldhirsch A, Winer EP, Coates AS, Gelber Rd, Piccart-Gebhart M, Thürlimann B, Senn HJ
Year : 2013
Journal : Ann Oncol
Volume : 24(9)
Pages : 2206-23

Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer.

Authors : Loi S, Michiels S, Lambrechts D, Fumagalli D, Claes B, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Piccart-Gebhart M, Joensuu H, Sotiriou C
Year : 2013
Journal : J. Natl. Cancer Inst.
Volume : 105(13)
Pages : 960-967

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

Authors : Goldhirsch A, Gelber Rd, Piccart-Gebhart M, de Azambuja E, Procter M, Suter TM, Jackisch C, Cameron D, Weber HA, Heinzmann D, Dal Lago L, Mcfadden E, Dowsett M, Untch M, Gianni L, Bell R, Köhne CH, Vindevoghel A, Andersson M, Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J
Year : 2013
Journal : Lancet
Volume : 382(9897)
Pages : 1021-8

CD4+ follicular helper T cell infiltration predicts breast cancer survival.

Authors : Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G, Veys I, Haibe-Kains B, Singhal SK, Michiels S, Rothé F, Salgado R, Duvillier H, Ignatiadis M, Desmedt C, Bron D, Larsimont D, Piccart-Gebhart M, Sotiriou C, Willard-Gallo K
Year : 2013
Journal : J Clin Invest
Volume : 123(7)
Pages : 2873-92

Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.

Authors : Burris HA, Lebrun F, Rugo HS, Beck JT, Piccart-Gebhart M, Neven P, Baselga J, Petrakova K, Hortobagyi GN, Komorowski A, Chouinard E, Young R, Gnant M, Pritchard KI, Bennett L, Ricci JF, Bauly H, Taran T, Sahmoud T, Noguchi S
Year : 2013
Journal : Cancer
Volume : 119(10)
Pages : 1908-15

Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis.

Authors : Azim HA, Singhal S, Ignatiadis M, Desmedt C, Fumagalli D, Veys I, Larsimont D, Piccart-Gebhart M, Michiels S, Sotiriou C
Year : 2013
Journal : PLoS One
Volume : 8(4)
Pages : e62451

Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial.

Authors : Criscitiello C, Azim HA, Agbor-Tarh D, de Azambuja E, Piccart-Gebhart M, Baselga J, Eidtmann H, Di Cosimo S, Bradbury I, Rubio IT
Year : 2013
Journal : Ann Oncol
Volume : 24(8)
Pages : 1980-5

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.

Authors : Saini KS, Loi S, de Azambuja E, Metzger-Filho O, Saini ML, Ignatiadis M, Dancey JE, Piccart-Gebhart M
Year : 2013
Journal : Cancer Treat Rev
Volume : 39(8)
Pages : 935-46

Magnitude of Trastuzumab Benefit in Patients With HER2-Positive, Invasive Lobular Breast Carcinoma: Results From the HERA Trial.

Authors : Metzger-Filho O, Procter M, de Azambuja E, Leyland-Jones B, Gelber Rd, Dowsett M, Loi S, Saini KS, Cameron D, Untch M, Smith I, Gianni L, Baselga J, Jackisch C, Bell R, Sotiriou C, Viale G, Piccart-Gebhart M
Year : 2013
Journal : J. Clin. Oncol.
Volume : 31(16)
Pages : 1954-60

Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study.

Authors : Hendlisz A, Golfinopoulos V, Deleporte A, Paesmans M, Mansy H, Garcia C, Peeters M, Annemans L, Vandeputte C, Maetens M, Borbath I, Dresse D, Houbier G, Fried M, Awada A, Piccart-Gebhart M, Laethem JL, Flamen P
Year : 2013
Journal : BMC Cancer
Volume : 13(1)
Pages : 190

HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab.

Authors : Zabaglo L, Stoss O, Rüschoff J, Zielinski D, Salter J, Arfi M, Bradbury I, Dafni U, Piccart-Gebhart M, Procter M, Dowsett M
Year : 2013
Journal : Ann Oncol
Volume : 24(11)
Pages : 2761-6

Autoimmune haemolytic anaemia in a patient treated with capecitabine.

Authors : Sideris S, Loizidou A, Georgala A, Lebrun F, Gil T, Awada A, Piccart-Gebhart M, Cardoso F
Year : 2013
Journal : Acta Clin Belg
Volume : 68(2)
Pages : 135-7

Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer.

Authors : Metzger-Filho O, Catteau A, Michiels S, Buyse M, Ignatiadis M, Saini KS, de Azambuja E, Fasolo V, Naji S, Canon JL, Delrée P, Coibion M, Cusumano P, Jossa V, Kains JP, Larsimont D, Richard V, Faverly D, Cornez N, Vuylsteke P, Vanderschueren B, Peyro-Saint-Paul H, Piccart-Gebhart M, Sotiriou C
Year : 2013
Journal : PLoS One
Volume : 8(8)
Pages : e66848

How Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast Cancer.

Authors : Pinto AC, de Azambuja E, Piccart-Gebhart M
Year : 2013
Journal : Breast Care (Basel)
Volume : 8(4)
Pages : 264-269

Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.

Authors : Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M
Year : 2013
Journal : Breast
Volume : 22 Suppl 2
Pages : S152-5

Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP).

Authors : Ades F, de Azambuja E, Daugaard G, Ameye L, Moulin C, Paesmans M, De Jong D, Decoster L, De Greve J, Ismael G, Møller AK, Piccart-Gebhart M, Awada A
Year : 2013
Journal : J Chemother
Volume : 25(4)
Pages : 239-46